Literature DB >> 16887867

Optimization of cardiac resynchronization guided by Doppler echocardiography: haemodynamic improvement and intraindividual variability with different pacing configurations and atrioventricular delays.

Martin Stockburger1, Suzanne Fateh-Moghadam, Aischa Nitardy, Holger Langreck, Wilhelm Haverkamp, Rainer Dietz.   

Abstract

AIMS: Cardiac resynchronization therapy (CRT) improves symptoms in heart failure patients with intraventricular conduction delay (IVCD). Different pacing modalities produce variable activation patterns and are likely to result in different haemodynamic changes. The objective of this study was to demonstrate acute haemodynamic changes with different CRT configurations. METHODS AND
RESULTS: In 26 patients (left ventricular ejection fraction 22.7+/-6.1%, QRS 176+/-29 ms, New York Heart Association III/IV 18/8), a CRT device was implanted. An optimization procedure was performed including left (LVPEI) and right ventricular pre-ejection intervals, interventricular mechanical delay (IVD), left ventricular filling fraction (FTc), and myocardial performance index (MPI) during left and biventricular pacing with three different atrioventricular (AV) delays. An optimal mode and AV delay were defined. LVPEI changed from 166+/-27 to 139+/-25 ms, IVD from 49+/-19 to 6+/-18 ms, MPI from 0.98+/-0.25 to 0.62+/-0.22, and FTc from 0.42+/-0.08 to 0.51+/-0.08 (P<0.001 for all comparisons). The variability was 39+/-20 ms for LVPEI, 55+/-24 ms for IVD, 0.11+/-0.07 for FTc, and 0.35+/-0.18 for MPI.
CONCLUSION: Optimized resynchronization in heart failure patients with IVCD produces marked acute improvement of the altered cardiac cycle timing. The variability of Doppler parameters with different CRT modalities underlines the necessity of individualized settings and suggests that the patients' benefit may be jeopardized without optimization.

Entities:  

Mesh:

Year:  2006        PMID: 16887867     DOI: 10.1093/europace/eul088

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  8 in total

Review 1.  Effects of cardiac resynchronization therapy on ventricular remodeling.

Authors:  Hind W Rahmouni; James N Kirkpatrick; Martin G St John Sutton
Journal:  Curr Heart Fail Rep       Date:  2008-03

2.  Impact of VV optimization in relation to left ventricular lead position: an acute haemodynamic study.

Authors:  Fakhar Z Khan; Munmohan S Virdee; Philip A Read; Peter J Pugh; David Begley; Simon P Fynn; David P Dutka
Journal:  Europace       Date:  2011-03-21       Impact factor: 5.214

Review 3.  The role of echocardiography in cardiac resynchronization therapy.

Authors:  Wojciech Mazur; Eugene S Chung
Journal:  Curr Heart Fail Rep       Date:  2009-03

Review 4.  Atrioventricular and interventricular delay optimization in cardiac resynchronization therapy: physiological principles and overview of available methods.

Authors:  Patrick Houthuizen; Frank A L E Bracke; Berry M van Gelder
Journal:  Heart Fail Rev       Date:  2011-05       Impact factor: 4.214

5.  Pre-ejection period by radial artery tonometry supplements echo Doppler findings during biventricular pacemaker optimization.

Authors:  Nima Taha; Jing Zhang; Reza Rafie; Rupesh Ranjan; Salima Qamruddin; Tasneem Z Naqvi
Journal:  Cardiovasc Ultrasound       Date:  2011-07-28       Impact factor: 2.062

6.  Statistical ranking of electromechanical dyssynchrony parameters for CRT.

Authors:  Serge Cazeau; Matthieu Toulemont; Philippe Ritter; Julien Reygner
Journal:  Open Heart       Date:  2019-01-21

7.  Reliability of a novel intracardiac electrogram method for AV And VV delay optimization and comparability to echocardiography procedure for determining optimal conduction delays in CRT patients.

Authors:  N Reinsch; C Buhr; S Huptas; T Buck; T Konorza; H Wieneke; R Erbel
Journal:  Indian Pacing Electrophysiol J       Date:  2009-03-15

8.  Cardiac resynchronization therapy during rest and exercise: comparison of two optimization methods.

Authors:  Cinzia Valzania; Maria J Eriksson; Giuseppe Boriani; Fredrik Gadler
Journal:  Europace       Date:  2008-08-27       Impact factor: 5.214

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.